^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    albumin-bound paclitaxel

    i
    Other names: ABI007, ABI-007, SNA-001, HC007
    Company:
    Generic mfg.
    Drug class:
    Tubulin inhibitor
    Related drugs:
    1d
    Effects of Proglumide with Chemotherapy on the Pancreatic Tumor Microenvironment: Phase 1 PROGEM Trial. (PubMed, Pharmaceutics)
    Background: The primary aim of this Phase 1 clinical trial was to study the safety and dose of a cholecystokinin receptor antagonist, proglumide, in combination with gemcitabine/nab-paclitaxel (GEM-NAB-P) in patients with metastatic pancreatic cancer. Proglumide demonstrates a favorable safety profile when combined with standard chemotherapy for metastatic pancreatic cancer. Its unique ability to remodel TME and alleviate cancer-related pain highlights its potential, warranting further research.
    P1 data • Journal
    |
    CD8 (cluster of differentiation 8)
    |
    gemcitabine • albumin-bound paclitaxel
    1d
    IN10018 Combination Therapy in Previously-treated Solid Tumors (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, InxMed (Shanghai) Co., Ltd. | N=72 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • ifebemtinib (IN10018)
    1d
    EPIK-B3: Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (clinicaltrials.gov)
    P3, N=137, Terminated, Novartis Pharmaceuticals | Trial completion date: Jan 2027 --> Feb 2026 | Active, not recruiting --> Terminated; The study was terminated following a strategic decision to halt recruitment due to persistently slow enrollment. This decision was not driven by any new or unexpected safety concerns.
    Trial completion date • Trial termination
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
    |
    PIK3CA mutation
    |
    Piqray (alpelisib) • albumin-bound paclitaxel
    1d
    Senescent cancer-associated fibroblasts drive early-stage lymph node metastasis in pancreatic cancer through lactate-mediated metabolic-epigenetic rewiring. (PubMed, Cancer Discov)
    We subsequently initiated a clinical trial (chidamide and nab-paclitaxel/gemcitabine plus anti-PD-1/CTLA-4) in metastatic PDAC patients and reported its preliminary promising results. Collectively, these findings reveal a closed link between cellular senescence and PDAC metastasis, offering the potential senolytic means to improve chemo-immunotherapy efficacy.
    Journal
    |
    CCR4 (C-C Motif Chemokine Receptor 4)
    |
    gemcitabine • albumin-bound paclitaxel • Epidaza (chidamide)
    2d
    Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=26, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3d
    Gemcitabine/nab-paclitaxel plus S-1 combination compared with gemcitabine/nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: a retrospective study. (PubMed, Ther Adv Med Oncol)
    No treatment-related mortality was found. The S-1 could be combined with GA as another potential triplet combination treatment option for advanced PDAC.
    Retrospective data • Journal
    |
    FoundationOne® CDx
    |
    gemcitabine • albumin-bound paclitaxel • Teysuno (gimeracil/oteracil/tegafur)
    4d
    ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=558, Recruiting, BioNTech SE | N=144 --> 558
    Enrollment change • Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    carboplatin • gemcitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • pumitamig (BNT327)
    4d
    TOURMALINE: Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (clinicaltrials.gov)
    P3, N=142, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2026 --> Sep 2026
    Trial completion date
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    4d
    C6461001: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (2025-523461-17-01)
    P2/3, N=203, Not yet recruiting, Pfizer Inc.
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed
    4d
    A clinical study of V940 in people with non-small cell lung cancer (V940-013) (2025-520902-37-00)
    P1/2, N=15, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • carboplatin • docetaxel • albumin-bound paclitaxel • intismeran autogene (mRNA-4157)
    4d
    Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=64, Recruiting, Wake Forest University Health Sciences | Trial completion date: Jul 2029 --> Jul 2028 | Trial primary completion date: Jul 2028 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan
    4d
    K-NADIR: Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC (clinicaltrials.gov)
    P2, N=30, Recruiting, Jianxing He
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    carboplatin • Tyvyt (sintilimab) • albumin-bound paclitaxel • Dupert (fulzerasib)